Sparsentan
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 103 publications
The latest pharmacotherapeutic options for the treatment of IgA nephropathy in the pediatric population.
Journal: Expert opinion on pharmacotherapy
Published: January 20, 2026
Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine.
Journal: Cureus
Published: December 21, 2025
Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan.
Journal: Journal of comparative effectiveness research
Published: November 20, 2025
Prevalence, resource utilization, and economic impact of kidney function and proteinuria in patients with focal segmental glomerulosclerosis.
Journal: The American journal of managed care
Published: November 12, 2025
IgA Nephropathy: An Overview of the Clinical Trials.
Journal: Kidney medicine
Published: October 06, 2025
Treatment of Recurrent IgA Nephropathy After Kidney Transplantation: Case Report and Comprehensive Literature Review.
Journal: Clinical case reports
Published: September 24, 2025
In brief: Embryotoxicity REMS removal for endothelin receptor antagonists.
Journal: The Medical letter on drugs and therapeutics
Published: September 09, 2025
Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report.
Journal: Swiss medical weekly
Published: August 14, 2025
Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy.
Journal: Expert review of clinical pharmacology
Published: July 10, 2025
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: July 07, 2025
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated Focal Segmental Glomerulosclerosis Enrolled in the DUPLEX Trial.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: June 26, 2025
Last Updated: 02/24/2026